Summit Therapeutics Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.
Effective on July 2, 2021 in connection with the departure of Michael Donaldson as Chief Financial Officer of Summit Therapeutics Inc. (the “Company”),
the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.
Extracted from this filing and checked against the source text.
Jeffrey R. Maranian was appointed as principal accounting officer at Summit Therapeutics Inc..
the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.View on SEC.gov
Michael Donaldson departed as Chief Financial Officer at Summit Therapeutics Inc..
Effective on July 2, 2021 in connection with the departure of Michael Donaldson as Chief Financial Officer of Summit Therapeutics Inc. (the “Company”),View on SEC.gov
Robert W. Duggan was appointed as interim principal financial officer at Summit Therapeutics Inc..
the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.